{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:42:31Z","timestamp":1789584151202,"version":"build-2803163510"},"reference-count":24,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gene silencing by CpG island promoter hypermethylation has awakened the interest for DNA demethylating agents as chemotherapy drugs. Zebularine (1-[\u03b2-D-ribofuranosil]-1,2-dihydropyrimidin-2-1) has been recently described as a new DNA methylation inhibitor. Here we have studied its effects in a mouse model of radiation-induced lymphomagenesis using nuclear magnetic resonance (NMR) and positron emission tomography (PET). All control animals presented large thymic T lymphomas and died between 4 and 5.5 months. In contrast, 40% (12 of 30) of zebularine-treated animals were still alive after 1 year (Kaplan-Meier P &lt; .001). NMR and PET imaging showed that surviving animals presented a thymus structure\/volume similar to normal mice of the same age. Most important, zebularine demonstrated a complete lack of toxicity in nonirradiated control mice. DNA hypomethylation induced by zebularine occurred in association with depletion in extractable DNA methyltransferase 1 protein. Thus, our data support the role of zebularine as a DNA demethylating agent with antitumor activity and little toxicity.<\/jats:p>","DOI":"10.1182\/blood-2005-05-2033","type":"journal-article","created":{"date-parts":[[2005,10,26]],"date-time":"2005-10-26T07:33:44Z","timestamp":1130312024000},"page":"1174-1177","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":55,"title":["The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma"],"prefix":"10.1182","volume":"107","author":[{"given":"Michel","family":"Herranz","sequence":"first","affiliation":[{"name":"From the Cancer Epigenetics Laboratory and the Animal Facility Unit, Spanish National Cancer Centre (CNIO); the Instituto de Estudios Biofuncionales and the Pathology Department, School of Veterinary, Complutense University of Madrid; and the Medical Image Laboratory, Department of Experimental Surgery, University Hospital Gregorio Maran\u0303o\u0301n, Madrid, Spain; and the Laboratory of Medical Chemistry, National Cancer Institute, National Institutes of Health (NIH), Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Marti\u0301n-Caballero","sequence":"additional","affiliation":[{"name":"From the Cancer Epigenetics Laboratory and the Animal Facility Unit, Spanish National Cancer Centre (CNIO); the Instituto de Estudios Biofuncionales and the Pathology Department, School of Veterinary, Complutense University of Madrid; and the Medical Image Laboratory, Department of Experimental Surgery, University Hospital Gregorio Maran\u0303o\u0301n, Madrid, Spain; and the Laboratory of Medical Chemistry, National Cancer Institute, National Institutes of Health (NIH), Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario F.","family":"Fraga","sequence":"additional","affiliation":[{"name":"From the Cancer Epigenetics Laboratory and the Animal Facility Unit, Spanish National Cancer Centre (CNIO); the Instituto de Estudios Biofuncionales and the Pathology Department, School of Veterinary, Complutense University of Madrid; and the Medical Image Laboratory, Department of Experimental Surgery, University Hospital Gregorio Maran\u0303o\u0301n, Madrid, Spain; and the Laboratory of Medical Chemistry, National Cancer Institute, National Institutes of Health (NIH), Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesu\u0301s","family":"Ruiz-Cabello","sequence":"additional","affiliation":[{"name":"From the Cancer Epigenetics Laboratory and the Animal Facility Unit, Spanish National Cancer Centre (CNIO); the Instituto de Estudios Biofuncionales and the Pathology Department, School of Veterinary, Complutense University of Madrid; and the Medical Image Laboratory, Department of Experimental Surgery, University Hospital Gregorio Maran\u0303o\u0301n, Madrid, Spain; and the Laboratory of Medical Chemistry, National Cancer Institute, National Institutes of Health (NIH), Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juana Maria","family":"Flores","sequence":"additional","affiliation":[{"name":"From the Cancer Epigenetics Laboratory and the Animal Facility Unit, Spanish National Cancer Centre (CNIO); the Instituto de Estudios Biofuncionales and the Pathology Department, School of Veterinary, Complutense University of Madrid; and the Medical Image Laboratory, Department of Experimental Surgery, University Hospital Gregorio Maran\u0303o\u0301n, Madrid, Spain; and the Laboratory of Medical Chemistry, National Cancer Institute, National Institutes of Health (NIH), Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Desco","sequence":"additional","affiliation":[{"name":"From the Cancer Epigenetics Laboratory and the Animal Facility Unit, Spanish National Cancer Centre (CNIO); the Instituto de Estudios Biofuncionales and the Pathology Department, School of Veterinary, Complutense University of Madrid; and the Medical Image Laboratory, Department of Experimental Surgery, University Hospital Gregorio Maran\u0303o\u0301n, Madrid, Spain; and the Laboratory of Medical Chemistry, National Cancer Institute, National Institutes of Health (NIH), Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Marquez","sequence":"additional","affiliation":[{"name":"From the Cancer Epigenetics Laboratory and the Animal Facility Unit, Spanish National Cancer Centre (CNIO); the Instituto de Estudios Biofuncionales and the Pathology Department, School of Veterinary, Complutense University of Madrid; and the Medical Image Laboratory, Department of Experimental Surgery, University Hospital Gregorio Maran\u0303o\u0301n, Madrid, Spain; and the Laboratory of Medical Chemistry, National Cancer Institute, National Institutes of Health (NIH), Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Esteller","sequence":"additional","affiliation":[{"name":"From the Cancer Epigenetics Laboratory and the Animal Facility Unit, Spanish National Cancer Centre (CNIO); the Instituto de Estudios Biofuncionales and the Pathology Department, School of Veterinary, Complutense University of Madrid; and the Medical Image Laboratory, Department of Experimental Surgery, University Hospital Gregorio Maran\u0303o\u0301n, Madrid, Spain; and the Laboratory of Medical Chemistry, National Cancer Institute, National Institutes of Health (NIH), Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111713075456600_REF1","doi-asserted-by":"crossref","unstructured":"Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002;21: 5427-5440.","DOI":"10.1038\/sj.onc.1205600"},{"key":"2019111713075456600_","doi-asserted-by":"crossref","unstructured":"Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349: 2042-2054.","DOI":"10.1056\/NEJMra023075"},{"key":"2019111713075456600_REF3","doi-asserted-by":"crossref","unstructured":"Laird PW. Cancer epigenetics. Hum Mol Genet. 2005;14: R65-76.","DOI":"10.1093\/hmg\/ddi113"},{"key":"2019111713075456600_REF4","doi-asserted-by":"crossref","unstructured":"Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429: 457-463.","DOI":"10.1038\/nature02625"},{"key":"2019111713075456600_","doi-asserted-by":"crossref","unstructured":"Esteller M. DNA methylation and cancer therapy: new developments and expectations. Curr Opin Oncol. 2005;17: 55-60.","DOI":"10.1097\/01.cco.0000147383.04709.10"},{"key":"2019111713075456600_REF6","doi-asserted-by":"crossref","unstructured":"Hackanson B, Guo Y, Lubbert M. The silence of the genes: epigenetic disturbances in haematopoietic malignancies. Expert Opin Ther Targets. 2005;9: 45-61.","DOI":"10.1517\/14728222.9.1.45"},{"key":"2019111713075456600_REF7","unstructured":"Pinto A, Zagonel V, Attadia V, et al. 5-Aza-2\u2032-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant. 1989;4: 28-32."},{"key":"2019111713075456600_","doi-asserted-by":"crossref","unstructured":"Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2\u2032-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000;18: 956-962.","DOI":"10.1200\/JCO.2000.18.5.956"},{"key":"2019111713075456600_REF9","doi-asserted-by":"crossref","unstructured":"Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2\u2032-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103: 1635-1640.","DOI":"10.1182\/blood-2003-03-0687"},{"key":"2019111713075456600_REF10","doi-asserted-by":"crossref","unstructured":"van den Bosch J, Lubbert M, Verhoef G, Wijermans PW. The effects of 5-aza-2\u2032-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res. 2004;28: 785-790.","DOI":"10.1016\/j.leukres.2003.11.016"},{"key":"2019111713075456600_REF11","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, O'Brien S, Cortes J, et al. Results of decitabine (5-aza-2\u2032deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 2003;98: 522-528.","DOI":"10.1002\/cncr.11543"},{"key":"2019111713075456600_REF12","doi-asserted-by":"crossref","unstructured":"Issa JP, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005;23: 3948-3956.","DOI":"10.1200\/JCO.2005.11.981"},{"key":"2019111713075456600_REF13","unstructured":"Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993;7: 21-29."},{"key":"2019111713075456600_REF14","doi-asserted-by":"crossref","unstructured":"Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20: 2429-2440.","DOI":"10.1200\/JCO.2002.04.117"},{"key":"2019111713075456600_REF15","doi-asserted-by":"crossref","unstructured":"Kornblith AB, Herndon JE 2nd, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002;20: 2441-2452.","DOI":"10.1200\/JCO.2002.04.044"},{"key":"2019111713075456600_REF16","doi-asserted-by":"crossref","unstructured":"Zhou L, Cheng X, Connolly BA, et al. Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol. 2002;321: 591-599.","DOI":"10.1016\/S0022-2836(02)00676-9"},{"key":"2019111713075456600_REF17","doi-asserted-by":"crossref","unstructured":"Cheng JC, Weisenberger DJ, Gonzales FA, et al. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol. 2004;24: 1270-1278.","DOI":"10.1128\/MCB.24.3.1270-1278.2004"},{"key":"2019111713075456600_REF18","doi-asserted-by":"crossref","unstructured":"Cheng JC, Yoo CB, Weisenberger DJ, et al. Preferential response of cancer cells to zebularine. Cancer Cell. 2004;6: 151-158.","DOI":"10.1016\/j.ccr.2004.06.023"},{"key":"2019111713075456600_REF19","doi-asserted-by":"crossref","unstructured":"Cheng JC, Matsen CB, Gonzales FA, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst. 2003;95: 399-409.","DOI":"10.1093\/jnci\/95.5.399"},{"key":"2019111713075456600_REF20","unstructured":"Newcomb EW, Steinberg JJ, Pellicer A. ras oncogenes and phenotypic staging in N-methylnitro-sourea- and gamma-irradiation-induced thymic lymphomas in C57BL\/6J mice. Cancer Res. 1988;48: 5514-5521."},{"key":"2019111713075456600_REF21","doi-asserted-by":"crossref","unstructured":"Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hall-mark of human cancer. Nat Genet. 2005;37: 391-400.","DOI":"10.1038\/ng1531"},{"key":"2019111713075456600_REF22","doi-asserted-by":"crossref","unstructured":"Fraga MF, Herranz M, Espada J. A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res. 2004;64: 5527-5534.","DOI":"10.1158\/0008-5472.CAN-03-4061"},{"key":"2019111713075456600_REF23","doi-asserted-by":"crossref","unstructured":"Malumbres M, Perez de Castro I, Santos J, et al. Inactivation of the cyclin-dependent kinase inhibitor p15INK4b by deletion and de novo methylation with independence of p16INK4a alterations in murine primary T-cell lymphomas. Oncogene.1997;14: 1361-1370.","DOI":"10.1038\/sj.onc.1200969"},{"key":"2019111713075456600_REF24","doi-asserted-by":"crossref","unstructured":"Yoo CB, Cheng JC, Jones PA. Zebularine: a new drug for epigenetic therapy. Biochem Soc Trans. 2004;32: 910-912.","DOI":"10.1042\/BST0320910"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/3\/1174\/1281578\/zh800306001174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/3\/1174\/1281578\/zh800306001174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T13:48:37Z","timestamp":1586526517000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/3\/1174\/22169\/The-novel-DNA-methylation-inhibitor-zebularine-is"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,1]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,2,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-05-2033","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,1]]}}}